-
Thematic Analysis
NewPharma M&A Deals Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Pharma Sector
-
Sector Analysis
NewHER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
Breast cancer (International Classification of Diseases, 10th Revision [ICD-10] codes C50.0–50.9) is a malignant tumor that originates in the breast tissue. Breast cancer cells begin inside the milk ducts of the breast. The earliest form (in situ) is not life-threatening and can be detected in early stages. The most common type of non-invasive (stage 0) types of breast cancer is called ductal carcinoma in situ (DCIS) (American Cancer Society, 2022; World Health Organization, 2024). DCIS refers to abnormal cells that...
-
Sector Analysis
NewFriedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in FRDA therapeutics. - More than 54,000 diagnosed prevalent cases of FRDA are anticipated in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for FRDA. - The marketed drugs space for FRDA is limited to just two approved drugs, Biogen's Skyclarys (omaveloxolone) is the leading drug in FRDA space. - R&D efforts in the FRDA space are limited, with no pre-registration drugs currently in the...
-
Sector Analysis
NewPost-Operative Pain (POP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in POP therapeutics. - In 2024, more than 34,000,000 incident cases of POP are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for POP. - Most marketed drugs for POP are enzyme inhibitors, followed by receptor agonists, by mechanism of action. - Phase III pipeline for POP is robust and includes 27 drugs, while pre-registration comprises four drugs. - Approximately 39.34% of the clinical trials...
-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Juvenile Macular Degeneration (Stargardt Disease) - Global Clinical Trials Review, 2024" provides an overview of Juvenile Macular Degeneration (Stargardt Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on Juvenile Macular Degeneration (Stargardt Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
NewHospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Hospital Acquired Pneumonia (HAP) - Global Clinical Trials Review, 2024" provides an overview of Hospital Acquired Pneumonia (HAP) Clinical trials scenario. This report provides top line data relating to the clinical trials on Hospital Acquired Pneumonia (HAP). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
NewDecompensated Cirrhosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Decompensated Cirrhosis - Global Clinical Trials Review, 2024" provides an overview of Decompensated Cirrhosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Decompensated Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
NewMycosis Fungoides Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Mycosis Fungoides - Global Clinical Trials Review, 2024" provides an overview of Mycosis Fungoides Clinical trials scenario. This report provides top line data relating to the clinical trials on Mycosis Fungoides. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
Testimonial
Your Drugs database is great, you can find all the information you want such as sales forecasts, countries, diseases, dates, clinical trials, and patent expiration. We are using this information to research the leading competitive products in our current project. In addition, we analyze the profiles of the leading products and use this information to set the differentiation profile of our own products and clarify our positioning. In terms of business forecasts, we are able to provide more objective figures by using the Drug Forecast and Market Analysis report series. The analysis of product share by disease (series of Drug Forecast and Market Analysis reports) is used for business feasibility assessment.”
The ability to evaluate or provide information on PJs in R&D from both product and disease perspectives (it is difficult to find a database that can be used comprehensively for both), stands GlobalData out from other providers. The release of new functions such as Likelihood of approval (LoA) analysis, which was something I wanted but did not exist, shows that GlobalData have done a good job of researching the industry and developing services from the customer’s perspective which is another positive.
GlobalData’s COVID-19 Bulletin, which is sent out several times a week, provides the latest information on COVID-19 related vaccines and therapeutics and is used as background information.
“GlobalData provides extensive and comprehensive Pharma and Biotech data along with spectacular customer support. I use their drug, trial and company data on a daily basis to support our sales and marketing efforts.”
“As a global biopharma R&D strategy consultancy, we use the GlobalData Pharma Intelligence platform across a broad spectrum of topics, it provides all key data in one place”